CD40 and rheumatoid arthritis: Taken together, CD40/CD40L antagonism is intended to reduce type I IFN secretion, inhibit inflammatory cytokine production by myeloid cells, and mitigate autoantibody production by suppressing B cell activation and memory response, and may emerge as a therapeutic strategy for RA and SLE.